Yong-Jian Geng, MD
Academic & Clinical Affiliations
Honors, Awards and Memberships
Publications
4862227
WLZWUBY4
1
alternatives-to-animal-experimentation
10
date
desc
Geng
43835
https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2226Y3AB2G%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gao%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGao%2C%20S.%2C%20Gao%2C%20S.%2C%20Sun%2C%20Z.%20et%20al.%20%282023%29.%20MicroRNA-322%20inhibition%20of%20calcification%20of%20arterial%20smooth%20muscle%20cells%20by%20regulation%20of%20galactosyltransferase%201-associating%20protein%20UBE2Q1%20and%20Runx2.%20%3Ci%3ECardiology%20Plus%3C%5C%2Fi%3E%20%3Ci%3E8%3C%5C%2Fi%3E%2C%2027%26%23x2013%3B36.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCP9.0000000000000039%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCP9.0000000000000039%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22MicroRNA-322%20inhibition%20of%20calcification%20of%20arterial%20smooth%20muscle%20cells%20by%20regulation%20of%20galactosyltransferase%201-associating%20protein%20UBE2Q1%20and%20Runx2%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shanshan%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Song%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhen%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Akesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harnath%20S.%22%2C%22lastName%22%3A%22Shelat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yongjian%22%2C%22lastName%22%3A%22Geng%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2201%5C%2F2023%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1097%5C%2FCP9.0000000000000039%22%2C%22ISSN%22%3A%222470-7511%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2F10.1097%5C%2FCP9.0000000000000039%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%2C%225WVJH2TN%22%5D%2C%22dateModified%22%3A%222023-06-08T13%3A55%3A05Z%22%7D%7D%2C%7B%22key%22%3A%226KLUE53T%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khachigian%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhachigian%2C%20L.%20M.%2C%20Black%2C%20B.%20L.%2C%20Ferdinandy%2C%20P.%20et%20al.%20%282022%29.%20Transcriptional%20regulation%20of%20vascular%20smooth%20muscle%20cell%20proliferation%2C%20differentiation%20and%20senescence%3A%20Novel%20targets%20for%20therapy.%20%3Ci%3EVascul%20Pharmacol%3C%5C%2Fi%3E%20%3Ci%3E146%3C%5C%2Fi%3E%2C%20107091.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.vph.2022.107091%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.vph.2022.107091%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transcriptional%20regulation%20of%20vascular%20smooth%20muscle%20cell%20proliferation%2C%20differentiation%20and%20senescence%3A%20Novel%20targets%20for%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Levon%20M.%22%2C%22lastName%22%3A%22Khachigian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%20L.%22%2C%22lastName%22%3A%22Black%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%5Cu00e9ter%22%2C%22lastName%22%3A%22Ferdinandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffaele%22%2C%22lastName%22%3A%22De%20Caterina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosalinda%22%2C%22lastName%22%3A%22Madonna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%5D%2C%22abstractNote%22%3A%22Vascular%20smooth%20muscle%20cells%20%28SMC%29%20possess%20a%20unique%20cytoplasticity%2C%20regulated%20by%20transcriptional%2C%20translational%20and%20phenotypic%20transformation%20in%20response%20to%20a%20diverse%20range%20of%20extrinsic%20and%20intrinsic%20pathogenic%20factors.%20The%20mature%2C%20differentiated%20SMC%20phenotype%20is%20physiologically%20typified%20transcriptionally%20by%20expression%20of%20genes%20encoding%20%5C%22contractile%5C%22%20proteins%2C%20such%20as%20SM%5Cu03b1-actin%20%28ACTA2%29%2C%20SM-MHC%20%28myosin-11%29%20and%20SM22%5Cu03b1%20%28transgelin%29.%20When%20exposed%20to%20various%20pathological%20conditions%20%28e.g.%2C%20pro-atherogenic%20risk%20factors%2C%20hypertension%29%2C%20SMC%20undergo%20phenotypic%20modulation%2C%20a%20bioprocess%20enabling%20SMC%20to%20de-differentiate%20in%20immature%20stages%20or%20trans-differentiate%20into%20other%20cell%20phenotypes.%20As%20recent%20studies%20suggest%2C%20the%20process%20of%20SMC%20phenotypic%20transformation%20involves%20five%20distinct%20states%20characterized%20by%20different%20patterns%20of%20cell%20growth%2C%20differentiation%2C%20migration%2C%20matrix%20protein%20expression%20and%20declined%20contractility.%20These%20changes%20are%20mediated%20via%20the%20action%20of%20several%20transcriptional%20regulators%2C%20including%20myocardin%20and%20serum%20response%20factor.%20Conversely%2C%20other%20factors%2C%20including%20Kruppel-like%20factor%204%20and%20nuclear%20factor-%5Cu03baB%2C%20can%20inhibit%20SMC%20differentiation%20and%20growth%20arrest%2C%20while%20factors%20such%20as%20yin%20yang-1%2C%20can%20promote%20SMC%20differentiation%20whilst%20inhibiting%20proliferation.%20This%20article%20reviews%20recent%20advances%20in%20our%20understanding%20of%20regulatory%20mechanisms%20governing%20SMC%20phenotypic%20modulation.%20We%20propose%20the%20concept%20that%20transcription%20factors%20mediating%20this%20switching%20are%20important%20biomarkers%20and%20potential%20pharmacological%20targets%20for%20therapeutic%20intervention%20in%20cardiovascular%20disease.%22%2C%22date%22%3A%22Oct%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.vph.2022.107091%22%2C%22ISSN%22%3A%221879-3649%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%2C%22MDTREPAF%22%5D%2C%22dateModified%22%3A%222022-11-04T15%3A27%3A45Z%22%7D%7D%2C%7B%22key%22%3A%222RBBMGKB%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Smolensky%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESmolensky%2C%20M.%20H.%2C%20Hermida%2C%20R.%20C.%2C%20Sackett-Lundeen%2C%20L.%20et%20al.%20%282022%29.%20Does%20patient-applied%20testosterone%20replacement%20therapy%20pose%20risk%20for%20blood%20pressure%20elevation%3F%20Circadian%20medicine%20perspectives.%20%3Ci%3ECompr%20Physiol%3C%5C%2Fi%3E%20%3Ci%3E12%3C%5C%2Fi%3E%2C%201%26%23x2013%3B20.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcphy.c220014%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcphy.c220014%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Does%20patient-applied%20testosterone%20replacement%20therapy%20pose%20risk%20for%20blood%20pressure%20elevation%3F%20Circadian%20medicine%20perspectives%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Smolensky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramon%20C.%22%2C%22lastName%22%3A%22Hermida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Sackett-Lundeen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramon%20G.%22%2C%22lastName%22%3A%22Hermida-Ayala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%5D%2C%22abstractNote%22%3A%22We%20reviewed%20medication%20package%20inserts%2C%20US%20Food%20and%20Drug%20Administration%20%28FDA%29%20reports%2C%20and%20journal%20publications%20concerning%20the%2010%20nonbiosimilar%20patient-applied%20%28PA%29%20testosterone%20%28T%29%20replacement%20therapies%20%28TRTs%29%20for%20intraday%20serum%20T%20patterning%20and%20blood%20pressure%20%28BP%29%20effects.%20Blood%20T%20concentration%20is%20circadian%20rhythmic%20in%20young%20adult%20eugonadal%20males%2C%20being%20highest%20around%20awakening%20and%20lowest%20before%20bedtime.%20T%20level%20and%2024%5Cu2009h%20variation%20are%20blunted%20in%20primary%20and%20secondary%20hypogonadism.%20Utilized%20as%20recommended%2C%20most%20PA-TRTs%20achieve%20nonphysiologic%20T%2024%5Cu2009h%20patterning.%20Only%20Androderm%5Cu00ae%20%2C%20an%20evening%20PA%20transdermal%20patch%2C%20closely%20replicates%20the%20normal%20T%20circadian%20rhythmicity.%20Accurate%20determination%20of%20risk%20for%20BP%20elevation%20and%20hypertension%20%28HTN%29%20by%20PA-TRTs%20is%20difficult%20due%20to%20limitations%20of%20office%20BP%20measurements%20%28OBPM%29%20and%20suboptimal%20methods%20and%20endpoints%20of%20ambulatory%20BP%20monitoring%20%28ABPM%29.%20OBPM%20is%20subject%20to%20%5C%22White%20Coat%5C%22%20pressor%20effect%20resulting%20in%20unrepresentative%20BP%20values%20plus%20masked%20normotension%20and%20masked%20HTN%2C%20causing%20misclassification%20of%20approximately%2045%25%20of%20trial%20participants%2C%20both%20before%20and%20during%20treatment.%20Change%20in%20guideline-recommended%20diagnostic%20thresholds%20over%20time%20causes%20misclassification%20of%20an%20additional%20approximately%2015%25%20of%20participants.%20ABPM%20is%20improperly%20incorporated%20into%20TRT%20safety%20trials.%20It%20is%20done%20for%2024%5Cu2009h%20rather%20than%20preferred%2048%5Cu2009h%3B%20BP%20is%20oversampled%20during%20wakefulness%2C%20biasing%20derived%2024%5Cu2009h%20mean%20values%3B%2024%5Cu2009h%20mean%20systolic%20and%20diastolic%20BP%20%28SBP%2C%20DBP%29%20are%20inappropriate%20primary%20outcomes%2C%20because%20of%20not%20being%20best%20predictors%20of%20risk%20for%20major%20acute%20cardiovascular%20events%20%28MACE%29%3B%20%5C%22daytime%5C%22%20and%20%5C%22nighttime%5C%22%20BP%20means%20referenced%20to%20clock%20time%20are%20reported%20rather%20than%20biologically%20relevant%20wake-time%20and%20sleep-time%20BP%20means%3B%20most%20importantly%2C%20asleep%20SBP%20mean%20and%20dipping%2C%20strongest%20predictors%20of%20MACE%2C%20are%20disregarded.%20%5Cu00a9%202022%20American%20Physiological%20Society.%20Compr%20Physiol%2012%3A%201-20%2C%202022.%22%2C%22date%22%3A%22Aug%2011%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcphy.c220014%22%2C%22ISSN%22%3A%222040-4603%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%2C%22VTWWYEIB%22%5D%2C%22dateModified%22%3A%222022-09-02T20%3A11%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22DLWZT38Z%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Geng%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cstrong%3EGeng%3C%5C%2Fstrong%3E%2C%20Y.-J.%2C%20Smolensky%2C%20M.%20H.%2C%20Sum-Ping%2C%20O.%20et%20al.%20%282022%29.%20Circadian%20rhythms%20of%20risk%20factors%20and%20management%20in%20atherosclerotic%20and%20hypertensive%20vascular%20disease%3A%20Modern%20chronobiological%20perspectives%20of%20an%20ancient%20disease.%20%3Ci%3EChronobiol%20Int%3C%5C%2Fi%3E%2C%201%26%23x2013%3B30.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F07420528.2022.2080557%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F07420528.2022.2080557%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Circadian%20rhythms%20of%20risk%20factors%20and%20management%20in%20atherosclerotic%20and%20hypertensive%20vascular%20disease%3A%20Modern%20chronobiological%20perspectives%20of%20an%20ancient%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Smolensky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Sum-Ping%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramon%22%2C%22lastName%22%3A%22Hermida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20J.%22%2C%22lastName%22%3A%22Castriotta%22%7D%5D%2C%22abstractNote%22%3A%22Atherosclerosis%2C%20a%20chronic%20inflammatory%20disease%20of%20the%20arteries%20that%20appears%20to%20have%20been%20as%20prevalent%20in%20ancient%20as%20in%20modern%20civilizations%2C%20is%20predisposing%20to%20life-threatening%20and%20life-ending%20cardiac%20and%20vascular%20complications%2C%20such%20as%20myocardial%20and%20cerebral%20infarctions.%20The%20pathogenesis%20of%20atherosclerosis%20involves%20intima%20plaque%20buildup%20caused%20by%20vascular%20endothelial%20dysfunction%2C%20cholesterol%20deposition%2C%20smooth%20muscle%20proliferation%2C%20inflammatory%20cell%20infiltration%20and%20connective%20tissue%20accumulation.%20Hypertension%20is%20an%20independent%20and%20controllable%20risk%20factor%20for%20atherosclerotic%20cardiovascular%20disease%20%28CVD%29.%20Conversely%2C%20atherosclerosis%20hardens%20the%20arterial%20wall%20and%20raises%20arterial%20blood%20pressure.%20Many%20CVD%20patients%20experience%20both%20atherosclerosis%20and%20hypertension%20and%20are%20prescribed%20medications%20to%20concurrently%20mitigate%20the%20two%20disease%20conditions.%20A%20substantial%20number%20of%20publications%20document%20that%20many%20pathophysiological%20changes%20caused%20by%20atherosclerosis%20and%20hypertension%20occur%20in%20a%20manner%20dependent%20upon%20circadian%20clocks%20or%20clock%20gene%20products.%20This%20article%20reviews%20progress%20in%20the%20research%20of%20circadian%20regulation%20of%20vascular%20cell%20function%2C%20inflammation%2C%20hemostasis%20and%20atherothrombosis.%20In%20particular%2C%20it%20delineates%20the%20relationship%20of%20circadian%20organization%20with%20signal%20transduction%20and%20activation%20of%20the%20renin-angiotensin-aldosterone%20system%20as%20well%20as%20disturbance%20of%20the%20sleep%5C%2Fwake%20circadian%20rhythm%2C%20as%20exemplified%20by%20shift%20work%2C%20metabolic%20syndromes%20and%20obstructive%20sleep%20apnea%20%28OSA%29%2C%20as%20promoters%20and%20mechanisms%20of%20atherogenesis%20and%20risk%20for%20non-fatal%20and%20fatal%20CVD%20outcomes.%20This%20article%20additionally%20updates%20advances%20in%20the%20clinical%20management%20of%20key%20biological%20processes%20of%20atherosclerosis%20to%20optimally%20achieve%20suppression%20of%20atherogenesis%20through%20chronotherapeutic%20control%20of%20atherogenic%5C%2Fhypertensive%20pathological%20sequelae.%22%2C%22date%22%3A%22June%2027%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F07420528.2022.2080557%22%2C%22ISSN%22%3A%221525-6073%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%2C%22ZSY78DJL%22%5D%2C%22dateModified%22%3A%222022-07-06T19%3A07%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22JAQMEAGT%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Geng%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cstrong%3EGeng%3C%5C%2Fstrong%3E%2C%20Y.-J.%20%282021%29.%20Atherosclerotic%20Plaque%20Progression%20to%20Clinical%20Events%3A%20A%20Clue%20From%2014C%20%26%23x201C%3BBomb%20Pulse%26%23x201D%3B%20Dating.%20%3Ci%3EJACC%20Basic%20Transl%20Sci%3C%5C%2Fi%3E%20%3Ci%3E6%3C%5C%2Fi%3E%2C%20746%26%23x2013%3B748.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacbts.2021.09.002%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacbts.2021.09.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Atherosclerotic%20Plaque%20Progression%20to%20Clinical%20Events%3A%20A%20Clue%20From%2014C%20%5C%22Bomb%20Pulse%5C%22%20Dating%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021%20Sep-Oct%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacbts.2021.09.002%22%2C%22ISSN%22%3A%222452-302X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%5D%2C%22dateModified%22%3A%222022-06-17T18%3A28%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22AV2EGHGH%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Madonna%20et%20al.%22%2C%22parsedDate%22%3A%222021-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMadonna%2C%20R.%2C%20Guarnieri%2C%20S.%2C%20Kov%26%23xE1%3Bcsh%26%23xE1%3Bzi%2C%20C.%20et%20al.%20%282021%29.%20Telomerase%5C%2Fmyocardin%20expressing%20mesenchymal%20cells%20induce%20survival%20and%20cardiovascular%20markers%20in%20cardiac%20stromal%20cells%20undergoing%20ischaemia%5C%2Freperfusion.%20%3Ci%3EJ%20Cell%20Mol%20Med%3C%5C%2Fi%3E%20%3Ci%3E25%3C%5C%2Fi%3E%2C%205381%26%23x2013%3B5390.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjcmm.16549%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjcmm.16549%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Telomerase%5C%2Fmyocardin%20expressing%20mesenchymal%20cells%20induce%20survival%20and%20cardiovascular%20markers%20in%20cardiac%20stromal%20cells%20undergoing%20ischaemia%5C%2Freperfusion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosalinda%22%2C%22lastName%22%3A%22Madonna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Guarnieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Csenger%22%2C%22lastName%22%3A%22Kov%5Cu00e1csh%5Cu00e1zi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aniko%22%2C%22lastName%22%3A%22G%5Cu00f6rbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zolt%5Cu00e1n%22%2C%22lastName%22%3A%22Giricz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Addolorata%22%2C%22lastName%22%3A%22Mariggi%5Cu00f2%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%5Cu00e9ter%22%2C%22lastName%22%3A%22Ferdinandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raffaele%22%2C%22lastName%22%3A%22De%20Caterina%22%7D%5D%2C%22abstractNote%22%3A%22Cardiac%20stromal%20cells%20%28CSCs%29%20contain%20a%20pool%20of%20cells%20with%20supportive%20and%20paracrine%20functions.%20Various%20types%20of%20mesenchymal%20stromal%20cells%20%28MSCs%29%20can%20influence%20CSCs%20in%20the%20cardiac%20niche%20through%20their%20paracrine%20activity.%20Ischaemia%5C%2Freperfusion%20%28I%5C%2FR%29%20leads%20to%20cell%20death%20and%20reduction%20of%20the%20paracrine%20activity%20of%20CSCs.%20The%20forced%20co-expression%20of%20telomerase%20reverse%20transcriptase%20%28TERT%29%20and%20myocardin%20%28MYOCD%29%2C%20known%20to%20potentiate%20anti-apoptotic%2C%20pro-survival%20and%20pro-angiogenic%20activities%20of%20MSCs%20isolated%20from%20the%20adipose%20tissue%20%28AT-MSCs%29%2C%20may%20increase%20CSC%20survival%2C%20favouring%20their%20paracrine%20activities.%20We%20aimed%20at%20investigating%20the%20hypothesis%20that%20CSCs%20feature%20improved%20resistance%20to%20simulated%20I%5C%2FR%20%28SI%5C%2FR%29%20and%20increased%20commitment%20towards%20the%20cardiovascular%20lineage%20when%20preconditioned%20with%20conditioned%20media%20%28CM%29%20or%20extracellular%20vesicles%20%28EV%29%20released%20from%20AT-MSCs%20overexpressing%20TERT%20and%20MYOCD%20%28T%5C%2FM%20AT-MSCs%29.%20Murine%20CSCs%20were%20isolated%20with%20the%20cardiosphere%20%28CSps%29%20isolation%20technique.%20T%5C%2FM%20AT-MSCs%20and%20their%20secretome%20improved%20spontaneous%20intracellular%20calcium%20changes%20and%20ryanodine%20receptor%20expression%20in%20aged%20CSps.%20The%20cytoprotective%20effect%20of%20AT-MSCs%20was%20tested%20in%20CSCs%20subjected%20to%20SI%5C%2FR.%20SI%5C%2FR%20induced%20cell%20death%20as%20compared%20to%20normoxia%20%2828%5Cu00a0%5Cu00b1%5Cu00a04%20vs%2010%5Cu00a0%5Cu00b1%5Cu00a03%25%2C%20P%5Cu00a0%3D%5Cu00a0.02%29.%20Pre-treatment%20with%20CM%20%2815%5Cu00a0%5Cu00b1%5Cu00a02%2C%20P%5Cu00a0%3D%5Cu00a0.02%29%20or%20with%20the%20EV-enriched%20fraction%20%2810%5Cu00a0%5Cu00b1%5Cu00a01%25%2C%20P%5Cu00a0%3D%5Cu00a0.02%29%20obtained%20from%20mock-transduced%20AT-MSCs%20in%20normoxia%20reduced%20cell%20death%20after%20SI%5C%2FR.%20The%20effect%20was%20more%20pronounced%20with%20CM%20%287%5Cu00a0%5Cu00b1%5Cu00a01%25%2C%20P%5Cu00a0%3D%5Cu00a0.01%29%20or%20the%20EV-enriched%20fraction%20%282%5Cu00a0%5Cu00b1%5Cu00a01%25%2C%20P%5Cu00a0%3D%5Cu00a0.01%29%20obtained%20from%20T%5C%2FM%20AT-MSCs%20subjected%20to%20SI%5C%2FR.%20In%20parallel%2C%20we%20observed%20lower%20expression%20of%20the%20apoptosis%20marker%20cleaved%20caspase-3%20and%20higher%20expression%20of%20cardiac%20and%20vascular%20markers%20eNOS%2C%20sarcomeric%20%5Cu03b1-actinin%20and%20cardiac%20actin.%20The%20T%5C%2FM%20AT-MSCs%20secretome%20exerts%20a%20cytoprotective%20effect%20and%20promotes%20development%20of%20CSCs%20undergoing%20SI%5C%2FR%20towards%20a%20cardiovascular%20phenotype.%22%2C%22date%22%3A%222021-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fjcmm.16549%22%2C%22ISSN%22%3A%221582-4934%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%5D%2C%22dateModified%22%3A%222022-06-17T18%3A27%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22WBXQZ9SA%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Smolensky%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESmolensky%2C%20M.%20H.%2C%20Hermida%2C%20R.%20C.%20and%20%3Cstrong%3EGeng%3C%5C%2Fstrong%3E%2C%20Y.-J.%20%282021%29.%20Chronotherapy%20of%20cardiac%20and%20vascular%20disease%3A%20timing%20medications%20to%20circadian%20rhythms%20to%20optimize%20treatment%20effects%20and%20outcomes.%20%3Ci%3ECurr%20Opin%20Pharmacol%3C%5C%2Fi%3E%20%3Ci%3E57%3C%5C%2Fi%3E%2C%2041%26%23x2013%3B48.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.coph.2020.10.014%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.coph.2020.10.014%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Chronotherapy%20of%20cardiac%20and%20vascular%20disease%3A%20timing%20medications%20to%20circadian%20rhythms%20to%20optimize%20treatment%20effects%20and%20outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Smolensky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramon%20C.%22%2C%22lastName%22%3A%22Hermida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%5D%2C%22abstractNote%22%3A%22Circadian%20rhythms%20impact%20cardiac%20and%20vascular%20pathophysiology%2C%20resulting%20in%2024-hour%20patterning%20of%20symptoms%20and%20life-threatening%5C%2Fending%20events%20%28chronopathology%29%2C%20plus%20kinetics%20and%20dynamics%20of%20medications%20%28chronopharmacology%29%2C%20resulting%20in%20administration-time%20differences%20in%20efficacy%20and%20safety.%20Scheduling%20medications%20according%20to%20circadian%20rhythm%20determinants%20%28chronotherapy%29%20can%20improve%20treatment%20effects%2C%20for%20example%2C%20before%20dinner%5C%2Fbedtime%20ingestion%20of%20cholesterol-lowering%20medications%20and%20acetylsalicylic%20acid%2C%20respectively%2C%20exerts%20enhanced%20control%20of%20hypercholesterolemia%20and%20after-awakening%20peak%20of%20platelet%20aggregation%3B%20bedtime%20ingestion%20of%20conventional%20hypertension%20medications%20optimizes%20normalization%20of%20sleep-time%20blood%20pressure%20%28BP%29-strongest%20independent%20BP%20marker%20of%20cardiovascular%20disease%20%28CVD%29%20risk-and%20most%20effectively%20prevents%20%28chronoprevention%29%20CVD%20morbidity%20and%20mortality.%20Exploration%20of%20chronotherapeutic%20strategies%20to%20improve%20management%20of%20cardiac%20arrhythmias%20and%20vascular%20pathophysiology%20is%20still%20awaited.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.coph.2020.10.014%22%2C%22ISSN%22%3A%221471-4973%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%5D%2C%22dateModified%22%3A%222022-06-17T18%3A27%3A55Z%22%7D%7D%2C%7B%22key%22%3A%223E579X6U%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wei%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWei%2C%20Z.-Y.%2C%20Qiao%2C%20R.%2C%20Chen%2C%20J.%20et%20al.%20%282021%29.%20The%20influence%20of%20pre-existing%20hypertension%20on%20coronavirus%20disease%202019%20patients.%20%3Ci%3EEpidemiol%20Infect%3C%5C%2Fi%3E%20%3Ci%3E149%3C%5C%2Fi%3E%2C%20e4.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268820003118%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268820003118%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20influence%20of%20pre-existing%20hypertension%20on%20coronavirus%20disease%202019%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhi-Yao%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rui%22%2C%22lastName%22%3A%22Qiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jian%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ji%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hui%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wen-Jun%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hua%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jing%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chong-Huai%22%2C%22lastName%22%3A%22Gu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hong-Jiang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mi%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cong%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yang%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hao-Yu%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hai-Yan%22%2C%22lastName%22%3A%22Qian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%5D%2C%22abstractNote%22%3A%22Hypertension%20represents%20one%20of%20the%20most%20common%20pre-existing%20conditions%20and%20comorbidities%20in%20Coronavirus%20disease%202019%20%28COVID-19%29%20patients.%20To%20explore%20whether%20hypertension%20serves%20as%20a%20risk%20factor%20for%20disease%20severity%2C%20a%20multi-centre%2C%20retrospective%20study%20was%20conducted%20in%20COVID-19%20patients.%20A%20total%20of%20498%20consecutively%20hospitalised%20patients%20with%20lab-confirmed%20COVID-19%20in%20China%20were%20enrolled%20in%20this%20cohort.%20Using%20logistic%20regression%2C%20we%20assessed%20the%20association%20between%20hypertension%20and%20the%20likelihood%20of%20severe%20illness%20with%20adjustment%20for%20confounders.%20We%20observed%20that%20more%20than%2016%25%20of%20the%20enrolled%20patients%20exhibited%20pre-existing%20hypertension%20on%20admission.%20More%20severe%20COVID-19%20cases%20occurred%20in%20individuals%20with%20hypertension%20than%20those%20without%20hypertension%20%2821%25%20vs.%2010%25%2C%20P%20%3D%200.007%29.%20Hypertension%20associated%20with%20the%20increased%20risk%20of%20severe%20illness%2C%20which%20was%20not%20modified%20by%20other%20demographic%20factors%2C%20such%20as%20age%2C%20sex%2C%20hospital%20geological%20location%20and%20blood%20pressure%20levels%20on%20admission.%20More%20attention%20and%20treatment%20should%20be%20offered%20to%20patients%20with%20underlying%20hypertension%2C%20who%20usually%20are%20older%2C%20have%20more%20comorbidities%20and%20more%20susceptible%20to%20cardiac%20complications.%22%2C%22date%22%3A%222021-01-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1017%5C%2FS0950268820003118%22%2C%22ISSN%22%3A%221469-4409%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%5D%2C%22dateModified%22%3A%222022-06-17T18%3A27%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22B3UTK7MT%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hermida%20et%20al.%22%2C%22parsedDate%22%3A%222021-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHermida%2C%20R.%20C.%2C%20Smolensky%2C%20M.%20H.%2C%20Balan%2C%20H.%20et%20al.%20%282021%29.%20Guidelines%20for%20the%20design%20and%20conduct%20of%20human%20clinical%20trials%20on%20ingestion-time%20differences%20-%20chronopharmacology%20and%20chronotherapy%20-%20of%20hypertension%20medications.%20%3Ci%3EChronobiol%20Int%3C%5C%2Fi%3E%20%3Ci%3E38%3C%5C%2Fi%3E%2C%201%26%23x2013%3B26.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F07420528.2020.1850468%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F07420528.2020.1850468%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Guidelines%20for%20the%20design%20and%20conduct%20of%20human%20clinical%20trials%20on%20ingestion-time%20differences%20-%20chronopharmacology%20and%20chronotherapy%20-%20of%20hypertension%20medications%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ram%5Cu00f3n%20C.%22%2C%22lastName%22%3A%22Hermida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Smolensky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Horia%22%2C%22lastName%22%3A%22Balan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20J.%22%2C%22lastName%22%3A%22Castriotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20J.%22%2C%22lastName%22%3A%22Crespo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaron%22%2C%22lastName%22%3A%22Dagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sherine%22%2C%22lastName%22%3A%22El-Toukhy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garret%20A.%22%2C%22lastName%22%3A%22FitzGerald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akio%22%2C%22lastName%22%3A%22Fujimura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ram%5Cu00f3n%20G.%22%2C%22lastName%22%3A%22Hermida-Ayala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%20P.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luiz%22%2C%22lastName%22%3A%22Menna-Barreto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artemio%22%2C%22lastName%22%3A%22Moj%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alfonso%22%2C%22lastName%22%3A%22Otero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20Daniel%22%2C%22lastName%22%3A%22Rudic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Schernhammer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%22%2C%22lastName%22%3A%22Skarke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomoko%20Y.%22%2C%22lastName%22%3A%22Steen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20E.%22%2C%22lastName%22%3A%22Young%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoyun%22%2C%22lastName%22%3A%22Zhao%22%7D%5D%2C%22abstractNote%22%3A%22Current%20hypertension%20guidelines%20fail%20to%20provide%20a%20recommendation%20on%20when-to-treat%2C%20thus%20disregarding%20relevant%20circadian%20rhythms%20that%20regulate%20blood%20pressure%20%28BP%29%20level%20and%2024%5Cu00a0h%20patterning%20and%20medication%20pharmacokinetics%20and%20pharmacodynamics.%20The%20ideal%20purpose%20of%20ingestion-time%20%28chronopharmacology%2C%20i.e.%20biological%20rhythm-dependent%20effects%20on%20the%20kinetics%20and%20dynamics%20of%20medications%2C%20and%20chronotherapy%2C%20i.e.%20the%20timing%20of%20pharmaceutical%20and%20other%20treatments%20to%20optimize%20efficacy%20and%20safety%29%20trials%20should%20be%20to%20explore%20the%20potential%20impact%20of%20endogenous%20circadian%20rhythms%20on%20the%20effects%20of%20medications.%20Such%20investigations%20and%20outcome%20trials%20mandate%20adherence%20to%20the%20basic%20standards%20of%20human%20chronobiology%20research.%20In-depth%20review%20of%20the%20more%20than%20150%20human%20hypertension%20pharmacology%20and%20therapeutic%20trials%20published%20since%201974%20that%20address%20the%20differential%20impact%20of%20upon-waking%5C%2Fmorning%20versus%20at-bedtime%5C%2Fevening%20schedule%20of%20treatment%20reveals%20diverse%20protocols%20of%20sometimes%20suboptimal%20or%20defective%20design%20and%20conduct.%20Many%20have%20been%20%5C%22time-of-day%2C%5C%22%20i.e.%20morning%20versus%20evening%2C%20rather%20than%20circadian-time-based%2C%20and%20some%20relied%20on%20wake-time%20office%20BP%20rather%20than%20around-the-clock%20ambulatory%20BP%20measurements%20%28ABPM%29.%20Additionally%2C%20most%20past%20studies%20have%20been%20of%20too%20small%20sample%20size%20and%20thus%20statistically%20underpowered.%20As%20of%20yet%2C%20there%20has%20been%20no%20consensual%20agreement%20on%20the%20proper%20design%2C%20methods%20and%20conduct%20of%20such%20trials.%20This%20Position%20Statement%20recommends%20ingestion-time%20hypertension%20trials%20to%20follow%20minimum%20guidelines%3A%20%28i%29%20Recruitment%20of%20participants%20should%20be%20restricted%20to%20hypertensive%20individuals%20diagnosed%20according%20to%20ABPM%20diagnostic%20thresholds%20and%20of%20a%20comparable%20activity%5C%2Fsleep%20routine.%20%28ii%29%20Tested%20treatment-times%20should%20be%20selected%20according%20to%20internal%20biological%20time%2C%20expressed%20by%20the%20awakening%20and%20bed%20times%20of%20the%20sleep%5C%2Fwake%20cycle.%20%28iii%29%20ABPM%20should%20be%20the%20primary%20or%20sole%20method%20of%20BP%20assessment.%20%28iv%29%20The%20minimum-required%20features%20for%20analysis%20of%20the%20ABPM-determined%2024%5Cu00a0h%20BP%20pattern%20ought%20to%20be%20the%20asleep%20%28not%20%5C%22nighttime%5C%22%29%20BP%20mean%20and%20sleep-time%20relative%20BP%20decline%2C%20calculated%20in%20reference%20to%20the%20activity%5C%2Frest%20cycle%20per%20individual.%20%28v%29%20ABPM-obtained%20BP%20means%20should%20be%20derived%20by%20the%20so-called%20adjusted%20calculation%20procedure%2C%20not%20by%20inaccurate%20arithmetic%20averages.%20%28vi%29%20ABPM%20should%20be%20performed%20with%20validated%20and%20calibrated%20devices%20at%20least%20hourly%20throughout%20two%20or%20more%20consecutive%2024%5Cu00a0h%20periods%20%2848%5Cu00a0h%20in%20total%29%20to%20achieve%20the%20highest%20reproducibility%20of%20mean%20wake-time%2C%20sleep-time%20and%2048%5Cu00a0h%20BP%20values%20plus%20the%20reliable%20classification%20of%20dipping%20status.%20%28vii%29%20Calculation%20of%20minimum%20required%20sample%20size%20in%20adherence%20with%20proper%20statistical%20methods%20must%20be%20provided.%20%28viii%29%20Hypertension%20chronopharmacology%20and%20chronotherapy%20trials%20should%20preferably%20be%20randomized%20double-blind%2C%20randomized%20open-label%20with%20blinded-endpoint%2C%20or%20crossover%20in%20design%2C%20the%20latter%20with%20sufficient%20washout%20period%20between%20tested%20treatment-time%20regimens.%22%2C%22date%22%3A%222021-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F07420528.2020.1850468%22%2C%22ISSN%22%3A%221525-6073%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%5D%2C%22dateModified%22%3A%222022-06-17T18%3A27%3A58Z%22%7D%7D%2C%7B%22key%22%3A%2294LGAWBT%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Geng%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%3Cstrong%3EGeng%3C%5C%2Fstrong%3E%2C%20Y.-J.%2C%20Madonna%2C%20R.%2C%20Hermida%2C%20R.%20C.%20et%20al.%20%282021%29.%20Pharmacogenomics%20and%20circadian%20rhythms%20as%20mediators%20of%20cardiovascular%20drug-drug%20interactions.%20%3Ci%3ECurr%20Res%20Pharmacol%20Drug%20Discov%3C%5C%2Fi%3E%20%3Ci%3E2%3C%5C%2Fi%3E%2C%20100025.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.crphar.2021.100025%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.crphar.2021.100025%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacogenomics%20and%20circadian%20rhythms%20as%20mediators%20of%20cardiovascular%20drug-drug%20interactions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yong-Jian%22%2C%22lastName%22%3A%22Geng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosalinda%22%2C%22lastName%22%3A%22Madonna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramon%20C.%22%2C%22lastName%22%3A%22Hermida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Smolensky%22%7D%5D%2C%22abstractNote%22%3A%22This%20article%20summarizes%20the%20current%20literature%20and%20documents%20new%20evidence%20concerning%20drug-drug%20interactions%20%28DDI%29%20stemming%20from%20pharmacogenomic%20and%20circadian%20rhythm%20determinants%20of%20therapies%20used%20to%20treat%20common%20cardiovascular%20diseases%20%28CVD%29%2C%20such%20as%20atherosclerosis%20and%20hypertension.%20Patients%20with%20CVD%20often%20have%20more%20than%20one%20pathophysiologic%20condition%2C%20namely%20metabolic%20syndromes%2C%20hypertension%2C%20hyperlipidemia%2C%20and%20hyperglycemia%2C%20among%20others%2C%20which%20necessitate%20polytherapeutic%20or%20polypharmaceutic%20management.%20Interactions%20between%20drugs%2C%20drugs%20and%20food%5C%2Ffood%20supplements%2C%20or%20drugs%20and%20genetic%5C%2Fepigenetic%20factors%20may%20have%20adverse%20impacts%20on%20the%20cardiovascular%20and%20other%20systems%20of%20the%20body.%20The%20mechanisms%20underlying%20cardiovascular%20DDI%20may%20involve%20the%20formation%20of%20a%20complex%20pharmacointeractome%2C%20including%20the%20absorption%2C%20distribution%2C%20metabolism%2C%20and%20elimination%20of%20drugs%2C%20which%20affect%20their%20respective%20bioavailability%2C%20efficacy%2C%20and%5C%2For%20harmful%20metabolites.%20The%20pharmacointeractome%20of%20cardiovascular%20drugs%20is%20likely%20operated%20with%20endogenous%20rhythms%20controlled%20by%20circadian%20clock%20genes.%20Basic%20and%20clinical%20investigations%20have%20improved%20the%20knowledge%20and%20understanding%20of%20cardiovascular%20pharmacogenomics%20and%20pharmacointeractomes%2C%20and%20additionally%20they%20have%20presented%20new%20evidence%20that%20the%20staging%20of%20deterministic%20circadian%20rhythms%2C%20according%20to%20the%20dosing%20time%20of%20drugs%2C%20e.g.%2C%20upon%20awakening%20vs.%20at%20bedtime%2C%20cannot%20only%20differentially%20impact%20their%20pharmacokinetics%20and%20pharmacodynamics%20but%20also%20mediate%20agonistic%5C%2Fsynergetic%20or%20antagonistic%20DDI.%20To%20properly%20manage%20CVD%20patients%20and%20avoid%20DDI%2C%20it%20is%20important%20that%20clinicians%20have%20sufficient%20knowledge%20of%20their%20multiple%20risk%20factors%2C%20i.e.%2C%20age%2C%20gender%2C%20and%20life%20style%20elements%20%28like%20diet%2C%20smoking%2C%20psychological%20stress%2C%20and%20alcohol%20consumption%29%2C%20and%20comorbidities%2C%20such%20as%20diabetes%2C%20hypertension%2C%20dyslipidemia%2C%20and%20depression%2C%20and%20the%20potential%20interactions%20between%20genetic%20or%20epigenetic%20background%20of%20their%20prescribed%20therapeutics.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.crphar.2021.100025%22%2C%22ISSN%22%3A%222590-2571%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WLZWUBY4%22%5D%2C%22dateModified%22%3A%222022-06-17T18%3A28%3A02Z%22%7D%7D%5D%7D
Gao, S., Gao, S., Sun, Z. et al. (2023). MicroRNA-322 inhibition of calcification of arterial smooth muscle cells by regulation of galactosyltransferase 1-associating protein UBE2Q1 and Runx2. Cardiology Plus 8, 27–36. https://doi.org/10.1097/CP9.0000000000000039.
Khachigian, L. M., Black, B. L., Ferdinandy, P. et al. (2022). Transcriptional regulation of vascular smooth muscle cell proliferation, differentiation and senescence: Novel targets for therapy. Vascul Pharmacol 146, 107091. https://doi.org/10.1016/j.vph.2022.107091.
Smolensky, M. H., Hermida, R. C., Sackett-Lundeen, L. et al. (2022). Does patient-applied testosterone replacement therapy pose risk for blood pressure elevation? Circadian medicine perspectives. Compr Physiol 12, 1–20. https://doi.org/10.1002/cphy.c220014.
Geng, Y.-J., Smolensky, M. H., Sum-Ping, O. et al. (2022). Circadian rhythms of risk factors and management in atherosclerotic and hypertensive vascular disease: Modern chronobiological perspectives of an ancient disease. Chronobiol Int, 1–30. https://doi.org/10.1080/07420528.2022.2080557.
Geng, Y.-J. (2021). Atherosclerotic Plaque Progression to Clinical Events: A Clue From 14C “Bomb Pulse” Dating. JACC Basic Transl Sci 6, 746–748. https://doi.org/10.1016/j.jacbts.2021.09.002.
Madonna, R., Guarnieri, S., Kovácsházi, C. et al. (2021). Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion. J Cell Mol Med 25, 5381–5390. https://doi.org/10.1111/jcmm.16549.
Smolensky, M. H., Hermida, R. C. and Geng, Y.-J. (2021). Chronotherapy of cardiac and vascular disease: timing medications to circadian rhythms to optimize treatment effects and outcomes. Curr Opin Pharmacol 57, 41–48. https://doi.org/10.1016/j.coph.2020.10.014.
Wei, Z.-Y., Qiao, R., Chen, J. et al. (2021). The influence of pre-existing hypertension on coronavirus disease 2019 patients. Epidemiol Infect 149, e4. https://doi.org/10.1017/S0950268820003118.
Hermida, R. C., Smolensky, M. H., Balan, H. et al. (2021). Guidelines for the design and conduct of human clinical trials on ingestion-time differences - chronopharmacology and chronotherapy - of hypertension medications. Chronobiol Int 38, 1–26. https://doi.org/10.1080/07420528.2020.1850468.
Geng, Y.-J., Madonna, R., Hermida, R. C. et al. (2021). Pharmacogenomics and circadian rhythms as mediators of cardiovascular drug-drug interactions. Curr Res Pharmacol Drug Discov 2, 100025. https://doi.org/10.1016/j.crphar.2021.100025.
